BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27059807)

  • 1. Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.
    Luca NJ; Burnett HF; Ungar WJ; Moretti ME; Beukelman T; Feldman BM; Schwartz G; Bayoumi AM
    Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1803-1811. PubMed ID: 27059807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
    Shi ZC; Fei HP; Wang ZL
    Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.
    Jalal H; O'Dell JR; Bridges SL; Cofield S; Curtis JR; Mikuls TR; Moreland LW; Michaud K
    Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1751-1757. PubMed ID: 27015606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.
    Park SK; Park SH; Lee MY; Park JH; Jeong JH; Lee EK
    Clin Ther; 2016 Nov; 38(11):2430-2446.e3. PubMed ID: 27771177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
    Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
    Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Bansback N; Phibbs CS; Sun H; O'Dell JR; Brophy M; Keystone EC; Leatherman S; Mikuls TR; Anis AH;
    Ann Intern Med; 2017 Jul; 167(1):8-16. PubMed ID: 28554192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.
    Hughes DA; Culeddu G; Plumpton CO; Wood E; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot Lacassagne S; Hardwick B; Hickey H; Woo P; Beresford MW; Ramanan AV
    Ophthalmology; 2019 Mar; 126(3):415-424. PubMed ID: 30336181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study.
    Levälampi T; Kärki J; Rebane K; Vähäsalo P; Malin M; Kröger L; Grönlund MM; Backström M; Pohjankoski H; Kautiainen H; Jokiranta S; Aalto K
    Pediatr Rheumatol Online J; 2023 Mar; 21(1):27. PubMed ID: 36949461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
    Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients.
    Tian F; Li JY; Wen ZH; Luo XW; Deng L; Zhang L; He JY
    Medicine (Baltimore); 2019 Nov; 98(48):e17750. PubMed ID: 31770193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Aalto K; Kröger L; Rebane K; Lahdenne P; Martikainen J
    Pediatr Rheumatol Online J; 2022 Nov; 20(1):97. PubMed ID: 36384562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.